"Turn" a single day by 20%, and the precision medical treatment of tumors has risen again?

"Turn" in a single day by 20%, and the "vane" of the tumor precision medical industry has risen again?

Source of amino observation: amino observation/Huang Kai

In the past year, companies in the precision medical industry in the tumor have not been better.

Whether it is a company represented by Ed Bio, or players led by American stocks, the stock price has encountered major challenges.

This is related to the environment, but it also has a certain connection with the business bottlenecks of various companies. For companies in the industry, in order to change market expectations, the core is to let everyone see confidence at the business level.

On August 31, the "vane" of the "vane" of the tumor precision medical industry seemed to let everyone see this possibility:

After the second quarter financial report was announced, the stock price of Ranshi Medical rose 20.62%.

So, does this mean that the "vane" has risen again?

/ 01 /

Accompanied by diagnosis of patients' business growth: encountering "bottlenecks" or because of the epidemic

From the perspective of digital, the performance of burning medicine is not as exciting as the stock price.

As shown in the figure below, the total revenue of stone burning medicine in the second quarter was 130 million yuan. Although the company's revenue still increases small year -on -year, the data is not optimistic. For an industry with almost no seasonal impact, the data from the previous month can obviously reflect the company's real business status.

Total revenue of Ranshi Medical includes patients' end income (mainly accompanied by diagnosis) and pharmaceutical company service revenue. Among them, the patient's end income has always been the company's main growth engine. At the beginning of the listing, Ranshi Medical was proud of the development of the two -wheel drive growth model of the "inside of the hospital+outside courtyard".

Looking at it carefully, the income performance of patients with stone burning medicine is not amazing. As shown in the figure below, whether it is inside or outside the hospital, it seems that a certain bottleneck encountered a certain bottleneck.

Of course, the poor performance in the first half of the year is related to the epidemic. A dense cities such as Beijing, Shanghai and other core tumor hospitals have successively appeared, which will inevitably affect patients' admission and samples for inspection.

Ranshi Medicine also stated that in regions outside Beijing and Shanghai, the test volume in the second quarter exceeded 60%. But as mentioned above, for tumor precision medical companies, the data is more objective.

From the time since the third quarter of last year, the growth rate of various businesses of Ranshi Medicine has actually slowed down. Therefore, even if there is no impact of the epidemic, whether the accompanying diagnostic business of the patient's patients can continue to grow, it is obviously questionable.

At least, the company's expectations for the future are not the accompanying diagnostic business of the patient.

/ 02 /

Future troiders: MRD, early screening and pharmaceutical companies services

According to the financial report of Ranshi Medicine in the second quarter, the company is looking forward to three -driving carriage in the future: early screening, MRD and pharmaceutical services.

This can also be understood that whether it is early screening, MRD (small lesion residue), or pharmaceutical companies, the domestic market is still in the "starting stage".

First look at the morning screening business. At present, only Nuohui's healthy colorectal cancer early screening product Chang Weiqing has been approved for listing, and there are many fields to be developed by the market. The research and development path of the selection of burning medicine is "pan -cancer species", which can theoretically provide a new choice.

Look at the MRD test again. MRD is not a new concept. Previously, it was widely used in blood tumors, which can be regarded as just needed products. Although MRD's commercialization prospects have been confirmed in blood tumors, it was still a desert restricted by technical factors. Nowadays, the emergence of liquid biopsy technology has allowed physical tumor MRD testing to usher in development opportunities.

Ranshi Medicine is also aiming at this opportunity to focus on the field of actual tumor. In March this year, the company's lung cancer MRD products have been launched, and it is planned to expand to other tumors such as colorectal cancer.

Pharmaceutical services are mainly to provide pharmaceutical companies with "accompanied by diagnosis+MRD testing" product R & D service. Whether it is accompanied by diagnosis or MRD testing, it is still in the rise of from scratch, and it is naturally a blue ocean.

In addition, the competition barriers of the three major businesses look higher. Take early screening, the development of pan -cancer early screening products requires a huge data foundation as a support, not no one has this ability.

The service business of pharmaceutical companies also has the characteristics of high barriers. In order to harvest the heart of pharmaceutical companies, precision medical players need not only show their strength on the product end, but also highlight the clinical and obtaining cards. Whether it is R & D, clinical, or obtaining certificates, it takes time to accumulate, so the strong is easy to be constant.

The entry market is in its infancy, and it has barriers to barriers, which is undoubtedly the favorite story of the capital market. If it can stand out in various business areas, it will inevitably change the capital market cognition.

/ 03 /

The cash on the account is enough to burn for 1 year, and the burning medicine needs to prove itself as soon as possible

Ranshi Medicine has begun to be a war of names.

At present, in the company's three -driving carriage, MRD testing products and pharmaceutical companies have entered a commercial stage. Among them, the service income of pharmaceutical companies has begun to take shape. As shown in the figure below, the income scale in the second quarter has reached 18.07 million yuan.

According to the financial report, the company's MRD testing product demand is also growing rapidly, but the specific income scale has not been disclosed. As for the subsequent performance, we also need to observe through the company's future financial report.

As for the early screening products of Burning Shi Medicine, it remains time to time from the stage of large -scale commercialization. In the first half of this year, the large -scale forward -looking clinical research of pan -burning medicine had just begun to work in the group. To a certain extent, whether the "three -driving horse -carrying" business can promote it smoothly, it will be the key to whether it can continue to lead the precision medical industry of the tumor.

After all, the company's net loss in the second quarter was 265 million yuan, burning 2.9 million per day. As of now, the company's cash reserve is 1.15 billion yuan, which can burn about 1 year.

For biotechnology companies that are listed but have not yet been profitable, re -financing is the key to supporting business development. The stock price decides whether it can successfully re -financing the core factor.

In other words, only as much as possible to continue to prove itself at the business level as much as possible, so that the market can see confidence in order to complete reinstatement and ensure that they can go further.

So, can the "three -driving troiders" make it as expected?

Disclaimer: This article is the content of Yaozhi.com, and the copyright of the pictures and text belongs to the original author. The purpose of reprinting is to pass more information, which does not represent the viewpoint of this platform. If the content, copyright and other issues are involved in the work, please leave a message on this platform, and we will delete it as soon as possible.

- END -